The Evolution of Glaucoma Surgery Through Clinical Trials: From Past to Present

Appelbaum J, Patel D, Greene L and Allison K

School of Medicine, New York Medical College, Valhalla, NY, USA
Prevention of Blindness from Glaucoma and Age Related Macular Degeneration, NY, USA
Northeastern University, Boston, MA, USA
University of Rochester, Flaum Eye Institute, Rochester, NY, USA

^*Correspondance to: Allison K 

 PDF  Full Text DOI: 10.25107/2474-1647.3722

Abstract

In 2020, there were 52.7 million cases of Glaucoma and projections indicate a continued, predominantly driven by expected growth in Asia and Africa. The disease burden is particularly high in Black individuals and other racial/ethnic minorities. Presently, there are a number of surgical interventions available to help combat the effects of Glaucoma, including: Trabeculectomy, Glaucoma Drainage Devices (GDD), and Micro-Invasive Glaucoma Surgery (MIGS). MIGS has seen a 400% increase in procedures between 2012 to 2016. However, studies have found that non- Hispanic Black patients, compared with non-Hispanic White patients, were associated with an increased risk of reoperation. Given the growing popularity of MIGS procedures, and potential complications, researchers need to pay particular attention to creating a diverse study population in clinical trials studying these interventions.

Keywords

#

Cite the article

Appelbaum J, Patel D, Greene L, Allison K. The Evolution of Glaucoma Surgery Through Clinical Trials: From Past to Present. Clin Surg. 2024; 9: 3722..